TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Bicara Therapeutics
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Bicara Therapeutics reported promising Phase 1b data for ficerafusp alfa, a bifunctional antibody, in treating HPV-negative head and neck squamous cell carcinoma. The 750mg weekly dose showed a 57% confirmed overall response rate and was well-tolerated when combined with pembrolizumab.

Insights
GLW   positive

Partnered with QuantumScape to develop ceramic battery separators, indicating potential for future collaboration


BCAX   positive

Demonstrated promising clinical trial results with a 57% overall response rate, consistent safety profile, and potential for meaningful patient outcomes in head and neck cancer treatment